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ABSTRACT
As only the type II topoisomerase is capable of
introducing negative supercoiling, DNA gyrase is
involved in crucial cellular processes. Although the
other domains of DNA gyrase are better understood,
the mechanism of DNA binding by the C-terminal
domain of the DNA gyrase A subunit (GyrA-CTD) is
less clear. Here, we investigated the DNA-binding
sites in the GyrA-CTD of Mycobacterium tuberculo-
sis gyrase through site-directed mutagenesis. The
results show that Y577, R691 and R745 are among
the key DNA-binding residues in M.tuberculosis
GyrA-CTD, and that the third blade of the GyrA-CTD
is the main DNA-binding region in M.tuberculosis
DNA gyrase. The substitutions of Y577A, D669A,
R691A, R745A and G729W led to the loss of super-
coiling and relaxation activities, although they had a
little effect on the drug-dependent DNA cleavage
and decatenation activities, and had no effect on
the ATPase activity. Taken together, these results
showed that the GyrA-CTD is essential to DNA
gyrase of M.tuberculosis, and promote the idea that
the M.tuberculosis GyrA-CTD is a new potential
target for drug design. It is the first time that
the DNA-binding sites in GyrA-CTD have been
identified.
INTRODUCTION
DNA gyrase (EC 5.99.1.3) is a predominantly prokaryotic
enzyme which has enzymatic properties distinct from other
type II topoisomerases, and has diverged signiﬁcantly during
evolution. It is an A2B2 tetramer that catalyzes the relaxation
of supercoiled DNA, catenation and decatenation of DNA
rings, and knotting and unknotting of duplex DNA (1–3).
It is also the only topoisomerase capable of introducing
negative supercoiling into closed-circular DNA in an ATP-
dependent manner (4,5). As an essential enzyme, DNA
gyrase is involved in crucial cellular processes such as repli-
cation, transcription and recombination (2,6), and is the target
of the quinolone drugs and aminocoumarin antibiotics (7).
These discoveries about gyrase have led to the expansion of
interest in its basic and clinical research.
The reaction mechanism of DNA gyrase is relatively well
understood and the crystal structures of the N-terminal
domain of GyrB (GyrB-NTD) (8–12), the N- and C-terminal
domains of GyrA (GyrA-NTD and GyrA-CTD) have alreadt
been solved (13–15). The functions of different domains of
the enzyme have also been identiﬁed. It is known that the
GyrB-NTD harbors the ATPase activity and binds to coumar-
ins; the C-terminal domain of GyrB (GyrB-CTD) is the
domain that interacts with GyrA and forms a complex capa-
ble of catalyzing DNA breakage and reunion (6,13). GyrA-
NTD is the catalytic center of gyrase, which harbors the
DNA cleavage–reunion activity (16,17), and GyrA-CTD is
involved in binding and wrapping the DNA (18–20). Further-
more, the active sites for the ATPase activity, the coumarin-
binding site in GyrB-NTD (10,11,21–27) and the sites of
interaction of the quinolones with GyrA and GyrB-CTD
(27–31), have also been identiﬁed. However, the active
sites of DNA-binding in GyrA-CTD and the mechanisms of
DNA binding are largely unknown.
It is known that GyrA-CTD is a non-speciﬁc DNA-binding
protein and has a unique role in DNA-wrapping and
T-segment presentation by gyrase (14,18,19). The GyrA-
CTD is catalytically inactive on its own, but can complement
the supercoiling activity of GyrA-NTD upon mixing (18).
GyrA-CTD has been shown to bind DNA independently
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mediated supercoiling (18,32). DNA wraps around gyrase in
a manner dependent upon the presence of the GyrA-CTD,
producing superhelicity, and that wrapping plays a crucial
role in controlling the directionality of supercoil induction
(33–35). Removal of the C-terminal domain abolishes the
wrapping of DNA around gyrase, eliminates the introduction
of supercoiling and converts gyrase into a conventional topoi-
somerase II (33). On the contrary, the addition of GyrA-CTD
results in restoration of the capacity to introduce negative
supercoils (36). The binding of gyrase to DNA can be shown
to involve the positive wrapping of DNA, and GyrA-CTD is
also capable of bending DNA by >180  over a 40 bp region
(14). The GyrA-CTD was predicted previously to have a six-
bladed b-propeller structure and it was believed that the
opposite side of the propeller is involved in interaction with
DNA (37). However, the ﬁrst published structure of GyrA-
CTD derived from the spirochete Borrelia burgdorferi
reveals an intriguing new fold designated a b-pinwheel
(14). Recently, the X-ray structure of Escherichia coli
GyrA-CTD was published (15). The E.coli GyrA-CTD
adopts a circular-shaped b-pinwheel fold, similar to the
B.burgdorferi GyrA-CTD; however, the B.burgdorferi
GyrA-CTD is ﬂat, whereas the E.coli GyrA-CTD is a spiral.
How does GyrA-CTD affect supercoiling activity in the
catalytic cycle? Which residues are involved in interacting
with DNA in the bending proposed to occur with GyrA-
CTD? Are there other roles for the GyrA-CTD in the activi-
ties of gyrase? We have investigated the active DNA-binding
sites in Mycobacterium tuberculosis GyrA-CTD using site-
directed mutagenesis, in an attempt to understand the role
of GyrA-CTD in the function of gyrase. The results showed
that the mutations of Y577A, D669A, R691A, R745A and
G729W led to loss of supercoiling, relaxation activities, but
had a little effect on drug cleavage and decatenation activities
and had no effect on ATPase activity, and showed that the
GyrA-CTD is essential to DNA gyrase of M.tuberculosis.I t
is the ﬁrst time that the DNA-binding sites in GyrA-CTD
have been identiﬁed.
MATERIALS AND METHODS
Bacterial strains and plasmids
Escherichia coli DH5a was used as the host for cloning
purposes. Strain BL21 (lDE3) and strain AD494 (lDE3)
were used for protein expression. Plasmids pET-20b and
pET-32a (Novagen) were used to construct vectors for over-
expression of M.tuberculosis GyrA and GyrB proteins,
respectively. Supercoiled plasmid pBR322 DNA was
extracted using the PureYield  Plasmid Midiprep System
(Promega Biological Products, Ltd. Joint Venture, China),
and relaxed plasmid pBR322 DNA was purchased from
John Innes Enterprises Ltd, UK.
Construction of GyrA and GyrB expression vectors
The gyrA and gyrB genes were both ampliﬁed from the
genomic DNA from M.tuberculosis H37Rv, and ligated to
pET20b and pET32a, respectively. The resulting plasmids,
pET20b-gyrA and pET32a-gyrB, were sequenced and the
sequences of the gyrA and gyrB genes were identical respec-
tively to the corresponding regions of the sequence with the
GenBank accession number NC 000962.
In vitro mutagenesis
To identify the DNA-binding sites, site-directed mutations
were introduced into the selected sites in gyrA gene by over-
lap PCR (38,39). All fragments were ligated into pET20b,
and were completely sequenced to conﬁrm the presence of
the site-directed mutations.
Protein overexpression and purification
Wild-type GyrA, all the mutants of GyrA and GyrB proteins
were overexpressed and puriﬁed by the same procedure.
E.coli BL21(lDE3)/pET20-gyrA and E. coli AD494(lDE3)/
pET32a-gyrB were induced by ﬁnal concentrations of
0.4 mM and 1 mM IPTG, respectively, at OD600 ¼ 0.6 for
4ha t2 5  C. Cells were harvested by centrifugation, resus-
pended in Binding Buffer [20 mM Tris–HCl (pH 7.9),
500 mM NaCl and 5 mM imidazole], and then disrupted
using an Ultrasonic Cell Disruptor. The disrupted suspension
was centrifuged and the supernatant was added to a column of
nickel chelate (Amersham Bioscience, USA) equilibrated
with Binding Buffer. The column was washed initially with
Washing Buffer [20 mM Tris–HCl (pH 7.9), 500 mM NaCl
and 60 mM imidazole] and the histidine-tagged protein was
eluted with Elution Buffer [20 mM Tris–HCl (pH 7.9),
500 mM NaCl and 250 mM imidazole]. According to the
purity in the SDS–PAGE, the peak fractions were pooled,
and concentrated by ultraﬁltration with Storing Buffer
[50 mM Tris–HCl (pH 7.9), 30% glycerol and 5 mM dithio-
threitol]. The proteins were centrifuged at 20000 g for 15 min
and then stored at  20 Co r 80 C in aliquots. The purity of
the protein was examined by SDS–PAGE and the concentra-
tion of proteins was measured by BCA protein assay kit
(Beyotime Biotechnology, China). To test the enzyme activi-
ties of the holoenzyme of gyrase A2B2, equal molar amounts
of GyrA and GyrB were mixed together at 25 C for 20 min
before use in assays.
Gel-retardation assay of DNA binding
Gel-retardation assays were performed using a PCR-ampliﬁed
240 bp DNA fragment containing the strong gyrase site
(SGS) from pBR322 (40) using speciﬁc primers (forward
primer, 50-CAA GCC GTC GAC ACT GGT CCC GCC
A-30; reverse primer, 50-CGC GAG GGA TCC TTG AAG
CTG-30). The 240 bp DNA (75 ng) was incubated with the
proteins in 20 ml DNA-binding buffer containing 20 mM
Tris–HCl (pH 7.5), 55 mM KCl, 5 mM DTT, 5% glycerol
and 4 mM MgCl2 for 30 min at 37 C (18). The samples
were then loaded onto a 9% native polyacrylamide
gel (29:1 acrylamide/N,N0-methylenebisacrylamide). Elec-
trophoresis was performed in 0.5 · TBE buffer (45 mM
Tris, 45 mM boric acid and 1 mM EDTA) containing
10 mM MgCl2 for 2–3 h at 4 C (18,40). Gels were stained
with ethidium bromide (0.7 mg/ml) for 20 min, and scanned
using a Bio-Rad gel documentation system. All assays were
performed at least three times.
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DNA supercoiling activity was assayed with recombinant
M.tuberculosis GyrA and GyrB proteins, and relaxed pBR322
DNA as a substrate. The assay reaction mixture (20 ml) con-
tained 20 mM–Tris·HCl (pH 7.5), 4 mM MgCl2, 50 mM KCl,
3 mM DTT, 1.5 mM ATP, 1.8 mM spermidine, 30 mg/l
E.coli tRNA, 20 mg/l BSA, 125 ng relaxed pBR322, and
GyrA and GyrB proteins (32,41). Various DNA gyrase con-
centrations from 0.01 to 10 mM were tested to determine
the optimal enzyme concentration and the enzyme reaction
condition was also optimized. The buffer, DNA and enzyme
mixtures were incubated for 3 h at 30 C. The reaction was ter-
minated by the addition of 5 ml Stop-Dye Buffer [5% (w/v)
SDS, 25% glycerol and 25 mg/ml bromophenol blue] and
2 ml solution of 20 mg/ml proteinase K at 37 C for 30 min
(40). The samples were loaded onto a 0.8% agarose gel con-
taining no ethidium bromide and run for 2.5 h at 90 V in TAE
(40 mM Tris acetate and 2 mM EDTA) running buffer at 4 C.
The gels were stained with ethidium bromide (0.7 mg/ml) for
30 min and were then visualized and quantiﬁed by using
the Bio-Rad gel documentation system. One unit of enzyme
activity was deﬁned as the concentration of enzyme that cat-
alyzes the conversion of 1 mg relaxed pBR322 DNA into the
completely supercoiled form in 3 h at 30 C (42).
The DNA relaxation assays were performed in the super-
coiling buffer without ATP and using supercoiled DNA as
substrate. The reaction mixtures (20 ml) were incubated
for 6 h at 37 C, and processed as described above for the
DNA supercoiling reaction. One unit of enzyme activity
was deﬁned as the concentration of enzyme that catalyzes
the conversion of 1 mg supercoiled pBR322 DNA into the
completely relaxed form in 1 h at 37 C (42).
DNA cleavage assays
DNA cleavage assays were carried out in the same buffer
as for DNA relaxation. The substrate was 75 ng supercoiled
pBR322 (33). Various norﬂoxacin (Sigma) concentrations
from 0.1 to 60 mg/ml were tested to determine the optimal
concentration. These assays were performed at 37 C for
different reaction time. The reactions were terminated by
the addition of 5 ml Stop-Dye Buffer and 2 ml of 20 mg/ml
proteinase K at 37 C for 30 min. The samples were loaded
onto a 0.8% agarose gel containing no ethidium bromide
and run for 2.5 h at 90 V in TAE running buffer (40 mM
Tris acetate and 2 mM EDTA) at 4 C. The DNA bands
were stained with ethidium bromide (0.7 mg/ml) for 30 min
and were then visualized and quantiﬁed by using the Bio-
Rad gel documentation system.
Decatenation of kDNA
Decatenation of kDNA was performed at 30 C for 30 min
using 100 ng of kDNA (John Innes Enterprises Ltd, UK)
as substrate (33). The reaction was terminated by adding
5 ml Stop-Dye buffer [1% (w/v) SDS, 25% glycerol and
25 mg/ml bromophenol blue] and 2 ml at 20 mg/ml protease
Ka t3 7  C for 30 min. The DNA products were analyzed
by agarose gel (1.0%) electrophoresis (2 h at 90 V in TAE
running buffer containing ethidium bromide). The DNA
bands were visualized and quantiﬁed by using the Bio-Rad
gel documentation system.
ATPase assays
ATPase activity was tested with the Micro-ATPase Assay Kit
(Nanjing Jiancheng research Institute, China) according to the
operation manual. Each GyrA mutant was mixed with GyrB
at an equal molar concentration at 25 C for  20 min. A
240 bp DNA, ampliﬁed from pBR322 plasmid, was added
to the reaction mixture at a ﬁnal concentration of 1 mg/ml.
The ATP was hydrolyzed by gyrase at 37 C and the reaction
was stopped after 10 min. The reaction mixture was cen-
trifuged at 2000 g for 10 min, a color reaction was carried
out with the supernatant, and 20 nM inorganic phosphate
was used as a control. The OD value was determined at
636 nm after 5 min. One unit of ATPase activity is deﬁned
as the amount of enzyme that catalyzes the hydrolysis of
1 mmol of ATP at 37 Ci n1h .
Surface plasmon resonance
Interactions of gyrase and DNA were investigated using
surface plasmon resonance (SPR) with the help of a BIAcore
3000 instrument (BIAcore AB, Uppsala, Sweden). A short
double-stranded DNA (dsDNA) was obtained by annealing
two synthesized complementary 30 bp ssDNA fragments, of
which one ssDNA was modiﬁed with biotin at its 50 end. A
260 bp dsDNA was ampliﬁed from the 1–260 bp region of
rpoB gene of M.tuberculosis by PCR. These two DNA frag-
ments, 30 bp dsDNA and 260 bp dsDNA, were ligated to
produce a 290 bp dsDNA which was then coupled to a
streptavidin-coated chip (SA sensor chip, BIAcore). This
coupling generated  400 response units (RU) on the SPR
machine. The running buffer containing 50 mM Tris–HCl
(pH 7.5), 55 mM KCl, 5 mM DTT, 4 mM MgCl2 and
0.005% (v/v) Tween-20 (43) was ﬁltered through Millipore
Film (pore size 0.22 mm) and degassed before use. Samples
containing the gyrase proteins (100 nM) were applied to
ﬂow across the chip surface at a rate of 20 ml/min.
RESULTS
Selection of the conserved residues for site-directed
mutagenesis and construction of the mutants
The sequence of M.tuberculosis H37Rv GyrA was compared
with that from B.burgdorferi and E.coli and the conserved
residues in the GyrA-CTD (between residues 499 and 810
of B.burgdorferi GyrA) were chosen (Figure 1). However,
the number of conserved residues chosen in this step is
large because gyrase itself is rather conserved in this region.
Therefore, we selected the residues that are likely to partici-
pate in DNA binding and DNA bending that are on the
surface of the structure of B.burgdorferi GyrA-CTD and are
polar (especially positively charged) (14,15,44). Based on
these criteria, 10 residues were chosen for further study
(Table 1). Residue R581 was not considered as it is absent
from the three-dimensional structure of B.burgdorferi
GyrA-CTD. Based on the structure of B.burgdorferi GyrA-
CTD, the ten conserved residues can be broadly divided
into two highly conserved groups, according to their locations
(Figures 1 and 2): the ﬁrst one is mostly located in the ﬁrst
blade, including E506, K519, H556 and Y574, and the
other is mostly located at the third blade, including D647,
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and K534 is located at the sixth blade. Considering that the
ﬁrst blade of GyrA-CTD is connecting and interacting
with GyrA-NTD, and the conserved residues of the third
blade could potentially contribute to a DNA-binding and
DNA-bending site in GyrA/ParC/RCC1 (14), our studies
are focused on the four conserved residues in the second con-
served domain, as they are all located in loops likely to bind
DNA (14,15,37). In the ﬁrst conserved domain, only the E506
was chosen for mutation as a comparison. Ala was introduced
into full-length GyrA by site-directed mutagenesis. E514A,
Y577A, D669A, R691A and R745A in M.tuberculosis
GyrA-CTD were constructed successfully and veriﬁed by
sequencing. G729W was introduced accidentally in the clon-
ing process and used as a comparison.
Production of the GyrA protein and GyrB protein
The expression levels of the mutated GyrA proteins were
similar to that of the wild-type GyrA protein (data not
shown). All the GyrA proteins and GyrB protein were in
the soluble fraction of the cell extract and were puriﬁed by
nickel-chelate chromatography. These proteins were assessed
for purity by SDS–PAGE, and were kept in storing buffer at
 20 Co r 80 C in aliquots.
Substitutions of Y577A, D669A, R691A and R745A lead
to total loss of DNA-binding activity of GyrA in the
absence of GyrB
The GyrA subunit is known to have DNA-binding activity in
the absence of GyrB (45). Six GyrA mutants were tested for
DNA binding. As shown in Figure 3, GyrA with the substitu-
tions G729W and E514A could bind DNA, whereas Y577A,
D669A, R691A and R745A did not have such activity. Both
the wild-type and the mutant G729W had about the same
binding activity, and the binding activity of E514A was
slightly less than that of the wild-type. These results suggest
that residues Y577, D669, R691 and R745 may participate in
DNA binding. Conversely, the E514 and G729 may not be
involved in DNA binding.
Mutants Y577A, D669A, R691A and R745A also lose
DNA-binding activity in the presence of GyrB
Gyrase is composed of GyrA and GyrB subunits; only when
GyrA is combined with GyrB the enzyme is able to carry
Figure 1. The homology mapping of GyrA-CTDs for selecting the conserved residues. 1, 2 and 3 are M.tuberculosis GyrA-CTD (506–838), B.burgdorferi GyrA-
CTD (499–810) and E.coli GyrA-CTD (530–853), respectively.
Table 1. The highly conserved residues selected from GyrA-CTD
Strains The selected conserved residues
B.burgdorferi E506 K519 K534 H556 Y569 Y574 D647 D660 R681 R735
E.coli E537 K550 K565 H587 Y600 Y605 D678 D692 R712 R766
M.tuberculosis E514 K527 K542 H564 Y577 Y582 D655 D669 R691 R745
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GyrA mutants in combination with GyrB was tested. As
shown in Figure 4, Y577A, R691A and R745A still had no
DNA-binding activity, but E514A and G729W had. The
results conﬁrmed that residues Y577, R691 and R745 not
only participate in DNA binding, but also have a key
role in this process; whereas residues E514 and G729 are
not key DNA-binding residues. D669A, in the presence of
GyrB, had weak DNA-binding activity, although alone it
had no DNA-binding activity (Figure 3), indicating that
D669 may have some role in DNA binding, although it is
not vital. These results imply that, as described previously
(46,47), GyrB cooperates with GyrA in DNA binding.
We found that the DNA-binding activity of wild-type
M.tuberculosis GyrA is nearly equal to that of the holoen-
zyme (A2B2).
Mutants Y577A, D669A, R691A, G729W and R745A
have no supercoiling activity in the presence of GyrB
The supercoiling activity of the GyrA mutants was tested in
the presence of GyrB. As indicated in Figure 5, no mutants
showed supercoiling activities, except for E514A. The latter
had supercoiling activity but lower than that of the wild-
type, reﬂecting the results of the DNA-binding assays. Inter-
estingly, in the presence of GyrB, G729W could bind DNA
(Figure 4), but had no supercoiling activity.
Figure 2. Selection of the conserved residues in GyrA. (A) The 10 highly conserved residues located in the crystal structure of B.burgdorferi GyrA-CTD. (B) The
homologous nine conserved residues located in the A strand of the crystal structure of E.coli GyrA-CTD; K565 (K534 in B.burgdorferi) is missing in
the structure. The five sites mutated successfully, E506A, Y569A, D660A, R681A and R735A, and one native mutation of G729W in M.tuberculosis (the
corresponding residue is N719 in B.burgdorferi) in the crystal structure of B.burgdorferi GyrA-CTD (C), and in the model of M.tuberculosis GyrA-CTD by
SWISS-MODEL (52) (D). The different colors of red, purple, black, pink, green, brown, grey, blue, yellow, gold and orange are E514, K527, K542, H564, Y577,
Y582, D655, D669, R691, G729 and R745 in M.tuberculosis GyrA-CTD, in (A), (B), (C) and (D), according to the homologous sites, respectively.
Figure 4. Gel-retardation assay of DNA-binding activity of the GyrA mutants
in the presence of GyrB. All GyrA mutants were mixed with GyrB at an equal
molar concentration (1.0 mM) at 25 C for  20 min, and incubated with 75 ng
of 240 bp DNA in 20 ml DNA-binding buffer. Lane 1, DNA sample without
any proteins; lane 2, GyrA alone; lanes 3–9, wild-type gyrase, E514A,
Y577A, D669A, R691A, G729W, R745A, respectively plus DNA and GyrB;
lane 10, GyrB only.
Figure 3. Gel-retardation assay of DNA-binding activity of the GyrA mutants
in the absence of GyrB. GyrA proteins (1.0 mM) were incubated with 75 ng of
240 bp DNA in 20 ml DNA-binding reaction buffer. Lane 1, DNA sample
without GyrA protein; lanes 2–8, WT (wild-type GyrA protein), E514A,
Y577A, D669A, R691A, G729W and R745A, respectively.
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presence of GyrB, show no relaxation activity
In the presence of GyrB, all mutants showed nearly no relax-
ation activity (Figure 6) with the exception of E514A and
G729W, but the relaxation activity of E514A was less than
that of the wild-type and that of G729W was weak. The
results show that residues Y577, D669, R691 and R745 are
also involved in the process of relaxing supercoiled DNA,
whereas E514 had some role in relaxing DNA. G729W
retains DNA-binding activity, but shows very little relaxation
activity.
Mutants D669A, R691A and R745A show less cleavage
activity than the wild type in the presence of GyrB
The drug dependent DNA cleavage activity of the GyrA
mutants was tested by incubating the GyrA mutants with
norﬂoxacin. As shown in Figure 7, the drug cleavage activity
of E514A was similar to the wild-type A2B2, those of Y577A
and G729A were nearly similar to that of the wild-type, and
those of D669A, R691A and R745A are less than that of the
wild-type. In the presence of GyrB, mutants D669A, R691A
and R745A could still cleave DNA completely by increasing
reaction time. This suggests that the GyrA-CTD is less impor-
tant for drug-dependent cleavage activity.
All mutants except for E514A, in the presence of GyrB,
showed less decatenation activity than the wild type
The decatenation activity of the GyrA mutants was tested
in the presence of GyrB. As shown in Figure 8A and B, all
mutants remained decatenation activity when the gyrase con-
centrations was 1 mM or 0.1 mM. However, lowering gyrase
concentration to 0.01 mM, mutants of D669A, R691A,
G729A and R745A showed no decatenation activity, whereas
the wild-type enzyme and E514A still had (Figure 8C).
The data suggests some facts that decatenation activity of
E514A is similar to that of the wild-type, TB gyrase is a
strong decatenase (40) and GyrA-CTD is less important for
decatenation reaction.
Six mutants have ATPase activity
It is known that GyrB alone or the gyrase holoenzyme (A2B2)
have ATPase activity, and that the activity of A2B2 can
be stimulated greatly by adding DNA (48). Such DNA-
dependent ATPase activity is likely to involve DNA wrap-
ping. The results (Figure 9) showed that all six mutants
have ATPase activity, nearly equal to that of the wild-type
A2B2, even in the existence of DNA.
Figure 7. The cleavage activity of GyrA mutants in the presence of GyrB. GyrA and GyrB were mixed together at an equal molar concentration (1.0 mM) at
25 C for  20 min before the assay. The concentration of norfloxacin was 60 mg/ml in the reaction buffer. Lane 1, supercoiled pBR322 only; lanes 2–8 are
supercoiled pBR322 treated with wild-type A2B2, E514A, Y577A, D669A, R691A, G729W and R745A, respectively, in (A), (B), (C) and (D). The reaction time
was (A) 5 min, (B) 10 min, (C) 15 min and (D) 30 min, respectively.
Figure 5. The supercoiling activity of the GyrA mutants in the presence of
GyrB. All GyrA mutants were mixed with GyrB in an equal molar
concentration (1.0 mM) at 25 C for  20 min before the assay. Lane 1,
relaxed pBR322 only; lanes 2–8, relaxed plasmid pBR322 treated with the
wild-type gyrase, E514A, Y577A, D669A, R691A, G729W and R745A,
respectively.
Figure 6. Relaxation activity of the GyrA mutants in the presence of GyrB.
GyrA and GyrB were mixed together at an equal molar concentration
(1.0 mM) at 25 C for  20 min prior to the assay. Lane 1, supercoiled pBR322
only; lanes 2–8, supercoiled pBR322 treated with wild-type A2B2, E514A,
Y577A, D669A, R691A, G729W and R745A, respectively.
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of interaction with DNA in the absence or presence
of GyrB
Although the DNA-binding activity of the six mutants was
measured by gel-retardation assay, it was not clear whether
the mutants were impaired just in wrapping or whether they
are unable to bind DNA at all. SPR technology, a sensitive
means to measure the molecular interactions, was employed
to study interaction between DNA and the GyrA mutants
either in the absence or presence of GyrB. The SPR 3000 sys-
tem contains a dual-channel measuring cell. Both reference
and sample channels have the same streptavidin-modiﬁed
sensor chip, but the chip in the sample channel was modiﬁed
with a 290 bp dsDNA through streptavidin–biotin interac-
tion. GyrA samples were repeatedly injected in the ﬂow-
through carrying buffer. Response signal (response unit,
RU) represents the binding of GyrA proteins to the bound
DNA. As shown in Figure 10, no response was observed
for the mutants Y577A, D691A and R745A with or without
GyrB, indicating that these mutants have completely lost
the capability of DNA binding. D669A did not bind DNA
in the absence of GyrB, but had a weak response signal
when GyrB was present, which agrees with the results of
the gel-retardation assay (Figure 4). Both E514A and
G729W could interact with DNA in the absence or presence
of GyrB with signiﬁcantly lowered binding signal, comparing
with the wild-type GyrA or A2B2. The sensorgram shows that
the binding mode of the G729W had changed from rapid to
slow association and dissociation kinetics.
DISCUSSION
As far as we know, gyrase is essential in all bacteria and has
not been found in humans or more generally in eukaryotes,
except recently in plant organelles (49,50). So gyrase is a
good therapeutic target and effective antibiotics have been
developed. However, increasing drug resistance is now a
serious problem and new agents against such resistance are
urgently needed (51). To date, most drugs act on GyrA-
NTD and GyrB-NTD, and quinolones probably act on
GyrB-CTD as well (1,27); mutations in these domains are
found in clinical isolates of different types of bacteria
leading to high resistance to existing antibiotics, including
M.tuberculosis. There are huge number of people with tuber-
culosis in the world and it is urgent to get more effective
drugs for treating this disease.
Since the 3D structure of M.tuberculosis GyrA is not yet
available, the homologous structures of GyrA-CTD from
both B.burgdorferi and E.coli were taken as references in
this study. There is a positively charged region around
the surface of the ﬁrst, fourth, ﬁfth and sixth blades in the
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
12 34 567
Different Proteins
A
T
P
a
s
e
 
A
c
t
i
v
i
t
y
 
(
×
1
0
3
 
U
/
µ
m
o
l
)
Figure 9. ATPase activity assay of the GyrA mutants in the presence of
GyrB. Column 1, wild-type A2B2; Columns 2–7, E514A, Y577A, D669A,
R691A, G729W and R745A, respectively. Gray columns, without adding
240 bp DNA; purple columns, with adding 240 bp DNA. Error bars show the
variations of at least three repeated measurements.
Figure 8. Decatenation activity of the GyrA mutants in the presence of GyrB. GyrA and GyrB were mixed together at an equal molar concentration at 25 C for
 20 min before the assay. Lane 1, catenated kDNA only; lanes 2–8, catenated kDNA treated with wild-type A2B2, E514A, Y577A, D669A, R691A, G729W and
R745A, respectively. Gyrase concentrations were 1 mMi n( A), 0.1 mMi n( B) and 0.01 mMi n( C), respectively.
5656 Nucleic Acids Research, 2006, Vol. 34, No. 19structure of B.burgdorferi GyrA-CTD, apparent from the
electrostatic surface (14), and a positively charged strip also
extending along the midriff of the structure of E.coli GyrA-
CTD (15). So their midriff is the obvious locus for interaction
with a contiguous stretch of duplex DNA, and the arginines
and lysines on the long loops could contact DNA (15).
B.burgdorferi GyrA-CTD can bind and bend DNA over
four of its six blades, and E.coli GyrA-CTD can bind DNA
containing complementary superhelicity (14,15). However,
there are two highly conserved regions in GyrA-CTD based
on homology mapping and the structure of B.burgdorferi
GyrA-CTD. The substitutions of D669A, R691A, R745A in
the second conserved region caused loss of DNA-binding
activity (Figures 3 and 4), so the third blade of GyrA-CTD
should be the main DNA-binding domain, which is consistent
with the previous work (37). Except for these sites, other sites
in other blades such as Y577, are also involved in DNA bind-
ing. According to the structure of B.burgdorferi GyrA-CTD,
it can be expected that R691 and R745 are the DNA-binding
sites as they are positively charged, lying on the loop and in
the midriff. However, Y577 and D669 are not lying in the
midriff region but still participate in DNA binding. At the
same time, previous work showed that there are two main
DNA-binding domains in DNA gyrase. The ﬁrst is the region
of the catalytic center, lying in the GyrA-NTD, and the other
is in the GyrA-CTD (1,6). However, GyrA-NTD alone has no
DNA-binding activity, but GyrA-CTD alone can still bind
DNA (18). Our data show that mutations of some residues
in GyrA-CTD can lead to complete loss of the DNA-binding
activity of the GyrA subunit or the A2B2 holoenzyme
(Figures 3 and 4). There must be some relation between the
two main DNA-binding domains, and maybe it is related
to the substrate preference of gyrase. Furthermore, the results
of gel-retardation assays were conﬁrmed by SPR (Figure 10).
It was also conﬁrmed that mutants of D669A, R691A, R745A
can not bind DNA at all by SPR. Thus, it seems that the
third blade is the main DNA-binding region in the GyrA-
CTD, and the GyrA-CTD is the main DNA-binding domain
in M.tuberculosis gyrase. These results are helpful to explain
the DNA-binding mechanism of gyrase.
GyrA-CTD was speculated to be involved in stabilizing the
DNA–protein complex (18). Previous work proved that the
removal of GyrA-CTD from E.coli gyrase results in loss of
the ability to supercoil DNA, a gain of the ability to relax
DNA, and a 30-fold increase in decatenation activity
(18,33). This suggests that GyrA-CTD is required for super-
coiling and has no role in relaxation and decatenation (18,33).
However, in our experiments, mutations of the proposed
DNA-binding sites in GyrA-CTD not only caused loss of
supercoiling activity, but also led to the loss of relaxation
(Figures 5 and 6). This suggested that, in M.tuberculosis,
GyrA-CTD has also a role in the process of relaxing super-
coiled DNA. But mutations of the proposed DNA-binding
sites in GyrA-CTD only have little effect on drug-dependent
cleavage activity (Figure 7) and decatenation activity
(Figure 8), which indicates that GyrA-CTD is less important
to these activities. This is consistent with the previous
report (33). It is known that the supercoiling DNA activities
of Mycobacterium bovis BCG is also much less than that of
E.coli (42), and Mycobacterium smegmatis gyrase exhibits
a stronger decatenase activity than E.coli gyrase (40). What
is the cause of the difference? The protein sequences of
Figure 10. SPR experiment of DNA-GyrA bindings. (A) Sensorgram of the GyrA and its mutants in absence of GyrB. (B) Sensorgram of the GyrA and its
mutants in presence of equal molar concentration (0.1 mM) of GyrB. The inserted table lists the kinetic constants derived from the sensorgrams.
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NTD, and the percent sequence similarities of M.tuberculosis
GyrA-CTD compared with B.burgdorferi GyrA-CTD and
E.coli GyrA-CTD only are 25.9 and 37.8%, respectively.
The b-pinwheel of B.burgdorferi GyrA-CTD is ﬂat, whereas
that of E.coli GyrA-CTD is a spiral (15). The E.coli GyrA-
CTD wraps DNA inducing substantial positive superhelicity,
whereas B.burgdorferi GyrA-CTD introduces a more modest
positive superhelicity (15). In other words, the diversity of
GyrA-CTD may cause the differences in structure and func-
tion. It also indicates that the GyrA-CTD is essential to
enzyme activities of M.tuberculosis DNA gyrase and the
precise catalytic mechanism of M.tuberculosis gyrase may
be different from that of other bacterial gyrases. It is very
interesting to ﬁnd that, although G729W still kept high-
DNA-binding activity, its supercoiling activity was almost
lost completely and its relaxation activity was much weak.
From the association and dissociation responses in SPR
(Figure 10), G729W has a different kinetic performance
from other mutants: G729W showed slowed association and
dissociation modes in the absence or presence of GyrB,
whereas the other two (the wild type and E514A) showed
fast association and dissociation process. This suggests that
binding DNA by G729W largely reduces enzyme activities.
It has been shown that GyrB has no DNA-binding activity
on its own (18), and consistent results were seen in this
study (Figure 4). However, a double mutation of S759R
and R760C in the C-terminal region of E.coli GyrB signiﬁ-
cantly reduced the DNA-binding activity of gyrase (46),
and the deletion of additional 165 residues in E.coli GyrB
also caused the almost complete loss of DNA-binding activity
(47). Thus GyrB also has an important role in binding DNA
by gyrase, despite its incapability of binding DNA by itself
in gel-retardation assays. GyrB should have effects on the
conformation of active sites of GyrA by interaction (28),
for GyrA only when combined with GyrB, has enzyme activi-
ties. In our study, the D669A mutant of GyrA combined with
GyrB turned out to have weak DNA-binding activity,
compared with the D669A mutant alone, which had no
DNA-binding activity at all (Figures 3, 4 and 10). However,
the mutants of Y577A, R691A and R745A can not interact
with DNA at all, even combined with GyrB (Figures 3,
4 and 10). Despite this, GyrB has the same effect on the
constants, although it is much weaker: the A2B2 holoenzyme
of WT, E514A and G729W has a lower association constant
and a higher dissociation constant than those alone
(Figure 10). In other words, GyrB retards the A2B2 holoen-
zyme to bind DNA, and accelerates the bound DNA to
deviate from A2B2, which may have an important role in
the catalytic mechanism of gyrase.
As shown in Figure 9, the mutations have no obvious effect
on the ATPase activity. Either in the presence or absence of
DNA, all mutations exhibited ATPase activities similar to
that of the wild-type A2B2, implying that the DNA-dependent
ATPase is not dependent on DNA binding by the GyrA-CTD.
Data reveal the DNA-stimulated ATPase activity is  2-fold
as high as the activity without stimulating by DNA. This
increase is much lower than that observed with E.coli gyrase
(48). The reason remains unknown.
GyrA-CTD is conserved among gyrases and exhibits
signiﬁcant sequence diversity from the other type II
topoisomerases. Eukaryotic topo IIs possess a CTD, but it
appears to be completely different in structure and function
from that of the prokaryotic CTD (1,2,6). Substitutions in
GyrA-CTD can lead to the loss of DNA-binding activity,
supercoiling activity and relaxation activities of M.tuberculo-
sis DNA gyrase, which stop crucial cellular processes in cells
and lead to cell death. It shows that the GyrA-CTD is essen-
tial to M.tuberculosis gyrase, and that drugs could be devised
more speciﬁcally to act on M.tuberculosis GyrA-CTD
more selectively, based on the divergence of different
bacterial GyrA-CTD. Thus, M.tuberculosis GyrA-CTD is a
potential new target for drug design. It also is the ﬁrst
time that the DNA-binding sites in GyrA-CTD have been
identiﬁed.
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